| 注册
首页|期刊导航|中国药业|重庆市药品安全风险管理策略研究

重庆市药品安全风险管理策略研究

李玲 黄哲

中国药业2026,Vol.35Issue(10):40-45,6.
中国药业2026,Vol.35Issue(10):40-45,6.DOI:10.3969/j.issn.1006-4931.2026.10.009

重庆市药品安全风险管理策略研究

Research on Drug Risk Management Strategies in Chongqing

李玲 1黄哲2

作者信息

  • 1. 沈阳药科大学工商管理学院,辽宁 沈阳 110016
  • 2. 重庆市药品监督管理局,重庆 401120
  • 折叠

摘要

Abstract

Objective To provide reference for improving drug risk management capabilities and risk prevention and control capacity.Methods The manufacturers and business entities of drugs,medical devices,and cosmetics in Chongqing were taken as the research subjects.The data on drug safety risk identification,assessment,and resolution reported by the district/county market supervision administrations and directly affiliated inspection bureaus from 2020 to 2024 were collected.Descriptive statistical methods were used to summarize and analyze indicators such as the number of identified risks,the number of recorded risks,the number of resolved risks,risk levels,and domain distribution.Combined with the mechanisms and practical approaches of drug risk management in Chongqing,the main problems in current work were identified.Results From 2020 to 2024,a total of 9 842 potential risks were identified in Chongqing,including 6 554 drug-related risks(66.59%),2 101 medical device-related risks(21.35%),and 1 187 cosmetic-related risks(12.06%).After assessment,1 282 risks were recorded in the database,all of which were resolved.Among the recorded risks,989 were general risks(77.15%),289 were relatively major risks(22.54%),four were major risks(0.31%),and no exceptionally major risks were found.The main risk included the absence of licensed pharmacists,retail pharmacies selling prescription drugs without a prescription,the sale and use of counterfeit or substandard medical devices,and cosmetic labels failing to comply with regulations.Meanwhile,it was identified that some grassroots units had weak risk management awareness,the regulatory workforce was insufficient,risk detection capabilities were insufficient,the quality of risk prevention and control was low,risk working mechanisms were incomplete,the primary responsibility of enterprises was inadequately fulfilled,and inter-departmental coordination was lacking.Conclusion Chongqing's drug regulation achieved full resolution of all recorded risks from 2020 to 2024.Nevertheless,continuous efforts are needed to strengthen risk management awareness,build a professional and specialized team of drug inspectors,improve risk detection capabilities,enhance the efficiency and quality of risk prevention and control through information technology and big data,and establish a long-term mechanism for fulfilling the primary responsibilities of enterprises and achieving multi-departmental coordination,so as to further improve the level of drug safety assurance.

关键词

重庆市/药品/安全风险管理/现状/对策

Key words

Chongqing/drug/risk management/current situation/countermeasures

分类

医药卫生

引用本文复制引用

李玲,黄哲..重庆市药品安全风险管理策略研究[J].中国药业,2026,35(10):40-45,6.

基金项目

国家药品监督管理局药品监管司药品安全风险会商机制课题[药监药管函[2024]364号]. ()

中国药业

1006-4931

访问量0
|
下载量0
段落导航相关论文